# EDGAR Filing Document

**Accession Number:** 0001426800
**File Stem:** 0000000000-26-002988
**Filing Date:** 2026-3
**Character Count:** 2367
**Document Hash:** 837633c52bdab3f65357ff6bceee3a80
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-002988.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0000000000-26-002988

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260324

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASSEMBLY BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001426800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-294459

**BUSINESS ADDRESS:**
- **STREET 1:** TWO TOWER PLACE
- **STREET 2:** 7TH FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (833) 409-4583

**MAIL ADDRESS:**
- **STREET 1:** TWO TOWER PLACE
- **STREET 2:** 7TH FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VENTRUS BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 20080211
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-116161

## Text-Extract

```

                                                           March 24, 2026

Jason A. Okazaki
Chief Executive Officer and President
Assembly Biosciences, Inc.
Two Tower Place, 7th Floor
South San Francisco, California 94080

       Re: Assembly Biosciences, Inc.
           Registration Statement on Form S-3
           Filed March 19, 2026
           File No. 333-294459
Dear Jason A. Okazaki:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    P. Michelle Gasaway, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._